- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterNCI CANCERLIT® Search: Retinoblastoma - October 2001
National Cancer Institute®
Last Modified: November 21, 2001
Table of Contents
1
UI - 20329341
AU - Singh AD; Shields CL; Shields JA; Sternberg P Jr
TI -
Occurrence of retinoblastoma and uveal melanoma in the same patient.
SO - Retina 2000;20(3):305-6
AD - Oncology Service, Wills Eye Hospital, Thomas Jefferson University,
Philadelphia, Pennsylvania 19107, USA. arunsighn@eyetumors.com
2
UI - 21085769
AU - Gamel J
TI -
Occurrence of retinoblastoma and uveal melanoma in the same period.
SO - Retina 2001;21(1):94-5
3
UI - 21279979
AU - Roth DB; Scott IU; Murray TG; Kaiser PK; Feuer WJ; Hughes JR; Rosa RH Jr
TI -
Echography of retinoblastoma: histopathologic correlation and serial
evaluation after globe-conserving radiotherapy or chemotherapy.
SO - J Pediatr Ophthalmol Strabismus 2001 May-Jun;38(3):136-43
AD - Department of Ophthalmology, Bascom Palmer Eye Institute, University of
Miami School of Medicine, Fla 33101, USA.
PURPOSE: To assess the sensitivity of echography in detecting
retinoblastoma, compare tumor features observed by echography with
histopathology data, and assess the usefulness of echography in serially
following retinoblastoma tumors after globe-conserving treatments.
METHODS: The medical and echography records of all patients treated for
retinoblastoma at the Bascom Palmer Eye Institute between 1991 and 1997
were reviewed. All eyes underwent pretreatment echographic evaluation,
and eyes treated with external beam radiotherapy, brachytherapy, or
chemotherapy underwent serial follow-up echography. RESULTS: Sixty-nine
eyes of 48 patients were identified. Echography demonstrated evidence of
retinoblastoma in 69 of 69 (100%) eyes and calcification in 63 (91.3%)
eyes. Histopathology was superior to echography in detecting optic nerve
invasion, extraocular extension, and presence of calcification.
CONCLUSION: Echography is a useful adjunct to indirect ophthalmoscopy in
establishing the diagnosis of retinoblastoma. While not as specific as
histopathology, echographic evaluation before and after treatment of
retinoblastoma permits monitoring of treatment response and may aid in
detecting recurrent tumor growth or failure to respond to treatment.
4
UI - 21279984
AU - Wang AG; Hsu WM; Hsia WW; Liu JH; Yen MY
TI -
Clinicopathologic factors related to metastasis in retinoblastoma.
SO - J Pediatr Ophthalmol Strabismus 2001 May-Jun;38(3):166-71
AD - Department of Ophthalmology, Taipei Veterans General Hospital, and the
Institute of Clinical Medicine, Taiwan.
PURPOSE: To investigate the orbital invasion and metastatic pattern in
retinoblastoma, and to analyze the correlation with other pathologic and
prognostic factors. METHODS: Pathologic and admission records of 45
patients with a pathologically confirmed diagnosis of retinoblastoma
during the past 20 years were reviewed. Clinical risk factors and
pathologic findings were analyzed for association with tumor
invasion/metastasis using chi-square, Fisher's exact, and Student's t
tests. RESULTS: Clinical risk factors such as exophthalmos, cataract,
and pseudohypopyon were significantly correlated with tumor
invasion/metastasis. The pathologic finding of choroid involvement was
highly predictive of tumor invasion/metastasis. Delayed enucleation (>3
months) also was significantly correlated with tumor
invasion/metastasis. CONCLUSION: Tumor invasion/metastasis is strongly
associated with various ocular, pathologic, and treatment outcome
factors. Identification of these risk factors may help plan treatment
regimens.
5
UI - 21411329
AU - Albert D; Syed N; Cancer Committee, College of American Pathologists
TI -
Protocol for the examination of specimens from patients with
retinoblastoma: a basis for checklists.
SO - Arch Pathol Lab Med 2001 Sep;125(9):1183-8
AD - Department of Ophthalmology, University of Wisconsin Hospital, Madison,
WI, USA.
6
UI - 21411341
AU - Liang SX; Lakshmanan Y; Woda BA; Jiang Z
TI -
A high-grade primary leiomyosarcoma of the bladder in a survivor of
retinoblastoma.
SO - Arch Pathol Lab Med 2001 Sep;125(9):1231-4
AD - Department of Pathology, University of Massachusetts Medical School,
Worcester, MA 01655, USA.
Second nonocular malignancies develop with increased incidence in
patients with hereditary retinoblastoma. Osteosarcoma is by far the most
common type with an incidence of up to 50%, followed by soft tissue
sarcomas. Visceral leiomyosarcoma is extremely rare and only 2 cases
have been reported in the past 2 decades, one in the liver and another
one in the urinary bladder, both of which developed after
cyclophosphamide therapy. Here we report a case of vesical
leiomyosarcoma that was diagnosed in a 49-year-old woman 47 years after
the diagnosis of a hereditary retinoblastoma. The patient's
retinoblastoma was treated with unilateral enucleation without adjuvant
radiation or chemotherapy. We believe that this is the first report of
vesical leiomyosarcoma occurring in a patient with retinoblastoma
without a prior history of radiation or chemotherapy. This report is
significant not only because of the rarity of vesical leiomyosarcoma as
a second nonocular tumor in retinoblastoma patients, but also because of
the infrequency of vesical leiomyosarcoma in general. We also
investigated the potential molecular pathogenesis of the leiomyosarcoma.
7
UI - 21453165
AU - Stannard C; Sealy R; Hering E; Korrubel J; Hill J; Barron A; Knowles R
TI -
Localized whole eye radiotherapy for retinoblastoma using a (125)I
applicator, "claws".
SO - Int J Radiat Oncol Biol Phys 2001 Oct 1;51(2):399-409
AD - Department of Radiation Oncology, Groote Schuur Hospital and University
of Cape Town, Cape Town, South Africa. clare@curie.uct.ac.za
PURPOSE: To treat children with retinoblastoma, who require whole eye
radiotherapy, with a specially designed (125)I applicator that
irradiates the eye while sparing the surrounding tissues. METHODS AND
MATERIALS: Under general anesthesia, a pericorneal ring is attached to
the 4 extraocular muscles, and 4 appendages, each loaded with (125)I
seeds, are inserted beneath the conjunctiva in-between each pair of
muscles and attached anteriorly to the ring. Twenty-nine eyes were
treated. Eighteen received a median dose of 28 Gy during 91 hours and 11
received 40 Gy during 122 hours, when the relative biologic
effectiveness was taken as 1 instead of 1.5. Six had received prior
chemotherapy. RESULTS: Twenty-four eyes were followed up for 2-157
months (median 29). Although 22 eyes responded, local control was
achieved in 13 patients, 3 of whom required additional treatment for new
tumors; a further 3 required additional treatment for tumor recurrence
as well as new tumors. One of these eyes was enucleated for neovascular
glaucoma. All 6 Group I-III eyes and 6 of 18 Group V eyes were retained
for 2-157 months (median 39), with good vision in 10 eyes. Three
developed cataracts 7, 8, and 12 years later, 1 of which has been
removed. CONCLUSIONS: This is a new way of irradiating the whole eye
with a minimal dose to the surrounding tissues. The treatment time is
only 5 days. It is effective in Groups I-III, but only 33% of Group V
eyes retained vision. No late cosmetic defects occurred.
8
UI - 21465268
AU - Abramson DH; Melson MR; Dunkel IJ; Frank CM
TI -
Third (fourth and fifth) nonocular tumors in survivors of
retinoblastoma.
SO - Ophthalmology 2001 Oct;108(10):1868-76
AD - Department of Ophthalmology, New York-Presbyterian Hospital, New York
Weill Cornell Medical Center, New York, New York, USA.
OBJECTIVE: This study aimed to investigate the incidence, timing,
pattern, and distribution of, as well as survival as a result of, third,
fourth, and fifth primary tumors in survivors of retinoblastoma. DESIGN:
This study was a retrospective case series of patients diagnosed with
retinoblastoma and a second malignant neoplasm. Records were examined
for demographic, prior treatment, and second tumor information, as well
as any evidence of the development of a third, fourth, or fifth
nonocular tumor. When possible, telephone inquiries were conducted for
follow-up. PARTICIPANTS: The study included 1506 patients followed in
the Ophthalmic Oncology Center at New York-Presbyterian Hospital, New
York Weill Cornell Medical Center, 211 of whom developed a second tumor
and had sufficient treatment data to be useful for analysis. MAIN
OUTCOME MEASURES: The development of third and additional nonocular
tumors and survival from these tumors were the primary outcome measures.
RESULTS: Of 211 second-tumor patients, 142 died before an additional
malignancy developed (median survival time, 1.8 +/- 0.3 years) and in
28, third tumors developed (5-year incidence rate, 11%; 10-year
incidence rate, 22%; median time to third tumor development, 5.8 +/- 8.3
years). The 5- and 10-year survival rates for this group were 41% and
30%, respectively (median survival time, 4.1 +/- 1.0 years). Of 28
patients in whom third tumors developed, 27 (96%) had received radiation
therapy for their retinoblastoma. The most common sites for third tumors
were soft tissues of the head (36% of all third tumors) and skin (36% of
all third tumors). In six patients, a fourth tumor developed, and in two
patients a fifth tumor developed. All fourth and fifth tumors were found
in the soft tissues of the head, the skin, or the bones. CONCLUSIONS:
Survivors of retinoblastoma in whom second malignant neoplasms develop
are at a higher risk for the development of additional tumors than they
were for the development of a second tumor. The locations and expected
ages at which additional tumors develop are consistent with the patterns
we have seen in second tumors.
9
UI - 92195558
AU - Weinstein GW; Weinstein BD
TI -
To see or to live? Case study and commentaries.
SO - Ophthalmic Surg 1992 Feb;23(2):140-3
AD - Department of Ophthalmology, West Virginia University School of
Medicine, Morgantown.
10
UI - 99334690
AU - Garber K
TI -
RAC nixes plan to treat retinoblastoma.
SO - Science 1999 Jun 25;284(5423):2066
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
